Use of bioresonance therapy in complex treatment of patients with diabetes mellitus type 2
- Authors: Kir’yanova VV1, Vorokhobina NV1, Makhramov ZK.1
-
Affiliations:
- North-Western State Medical University named after I.I. Mechnikov
- Issue: Vol 98, No 3 (2017)
- Pages: 334-337
- Section: Theoretical and clinical medicine
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/6478
- DOI: https://doi.org/10.17750/KMJ2017-334
- ID: 6478
Cite item
Full Text
Abstract
Aim. To evaluate the effectiveness of bioresonance therapy use in complex treatment of patients with diabetes mellitus type 2.
Methods. The treatment scheme including bioresonance therapy is offered for patients with diabetes mellitus type 2. All 413 patients were assigned to 3 comparable groups: the study group included 198 patients, control group - 72 patients, placebo group - 143 patients. Duration of diabetes in the study group was 5.47±0.37 years, in control group - 4.03±0.46 years, in placebo group - 4.97±0.39 years. All patients were treated according to the traditional scheme of treatment of type 2 diabetes. The study group in addition to pharmacotherapy received bioresonance therapy. Control group received only drug treatment and placebo group received drug therapy and bioresonance simulation procedures. All patients were checked for glycated hemoglobin, fasting plasma glucose, blood glucose 2 hours after a meal, urine glucose, and body mass index on admission and 3 months after treatment.
Results. Results of glycated hemoglobin, fasting plasma glucose, blood glucose 2 hours after a meal, urine glucose, and body mass index revealed that initially studied parameters in all three groups were high. After the bioresonance therapy in complex treatment of patients with diabetes type 2 in the study group all studied parameters were statistically significantly lower compared to control and placebo groups.
Conclusion. The obtained results indicate the effectiveness of bioresonance therapy use in complex treatment of patients with diabetes mellitus type 2.
About the authors
V V Kir’yanova
North-Western State Medical University named after I.I. Mechnikov
Author for correspondence.
Email: mazaho@mail.ru
Saint Petersburg, Russia
N V Vorokhobina
North-Western State Medical University named after I.I. Mechnikov
Email: mazaho@mail.ru
Saint Petersburg, Russia
Z Kh Makhramov
North-Western State Medical University named after I.I. Mechnikov
Email: mazaho@mail.ru
Saint Petersburg, Russia
References
- Гончар В.Н., Башнина Е.Б., Ворохобина Н.В. Сахарный диабет 2-го типа у лиц молодого возраста: этиология, патогенез, диагностика и лечение. Учебное пособие. СПб.: СПбМАПО. 2012; 22 с.
- Дедов И.И., Мельниченко Г.А. Эндокринология. Национальное руководство. М.: ГЭОТАР- Медиа. 2008; 352-463.
- Kaluz S., Kaluzova M., Stanbridge E.J. Regulation of gene expression by hypoxia: Integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. Clin. Chim. Acta. 2008; 395: 6-13. doi: 10.1016/j.cca.2008.05.002.
- Мельниченко Г.А. Практическая эндокринология. М.: Практическая медицина. 2009; 197 с.
- Lionetti L., Mollica M.P., Lombardi A. et al. From chronic overnutrition to insulin resistance: The role of fat-storing capacity and inflammation. Nutr. Metab. Cardiovasc. Dis. 2009; 19 (2): 146-152. doi: 10.1016/j.numecd.2008.10.010.
- McGill J.B., Bell D.S.H. Anemia and the role of erythropoietin in diabetes. J. Diabetes Complications. 2006; 20: 262-272. doi: 10.1016/j.jdiacomp.2005.08.001.
- Пономаренко Г.Н. Частная физиотерапия. М.: Медицина. 2005; 233-266.
- Недосугова T.В. Новые подходы к терапии сахарного диабета 2-го типа. РМЖ. 2006; 14 (13): 2-5.
- Холодова Е.А. Клиническая эндокринология. Руководство для врачей. М.: МИА. 2011; 704-706 с.
- Galle М. Die MORA-Bioresonanz therapie - eine komplementar medizinische methode. Arzt, Zahnarztund Naturheil verfahren. 2007; (1): 7-11.
- Лихарев В.В. Методические рекомендации для медицинского прибора биорезонансной терапии «DETA-BRT» НПП «Эллис». 2006; 102 с.
- Махрамов З.Х., Кирьянова В.В., Ворохобина Н.В. Способ лечения больных сахарным диабетом 2-го типа. Патент №2561837 РФ. Бюлл. №25 от 10.09.2015.
Supplementary files
